Cogent Biosciences
COGT
NASDAQ
IPO2018
about COGT
Cogent Biosciences develops innovative therapies for rare and serious diseases, with a focus on advancing treatments for conditions such as hereditary ATTR amyloidosis through its pipeline of biologics.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $32.76 | $36.15 | $31.00 | $2.07B | 23.29M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.50 | n/a | n/a | 0% | 0% | 0% |